A clinical trial conducted by the Massachusetts General Hospital Cancer Center, US, demonstrated that the antibody-drug conjugate sacituzumab govitecan (IMMU-132) can target cancer cells and shrink tumours in women with triple negative breast cancer (TNBC).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Developed by fusing a chemotherapy treatment to an antibody, the drug targets Trop-2 that is reported to be found at high levels on the surface of several cancer cells, to selectively deliver the active metabolite of irinotecan called SN-38.

It was found that the sacituzumab govitecan was well tolerated, and triggered early and durable responses in heavily pretreated patients.

The single-arm, multi-centre trial evaluated the efficacy and safety of sacituzumab govitecan in 69 patients with relapsed / refractory metastatic TNBC who have received at least one previous therapy.

The trial's primary endpoints were safety and objective response rate, while the secondary endpoints determined progression-free and overall survival.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"The trial's primary endpoints were safety and objective response rate, while the secondary endpoints determined progression-free and overall survival."

According to Cancer Research UK Professor Peter Schmid, while the responses to this treatment are promising, further investigation is required to find out which patients with TNBC are most likely to benefit from the treatment.

The results showed that the tumours shrank by 30% or more in 21 of the 69 women who received the drug.

While it is reported that tumours completely disappeared in two patients, about 70% experienced shrinkage to certain extent.

The drug will be further evaluated to study its effects in patients with earlier-stage disease as a combination therapy, as a treatment option for other forms of breast cancer.

Image: Massachusetts General Hospital. Photo: courtesy of InvictaHOG/Wikipedia.